The US Food and Drug Administration (FDA) has granted clearance to medical equipment firm Toshiba Medical’s new cardiovascular ultrasound Aplio i900.
A part of the firm's Aplio i-series ultrasound platform, Aplio i900 is claimed to be a cost-effective, less invasive and safer option for cardiac imaging compared to other radiation emitting modalities.
The new ultrasound enables clinicians to quickly and easily examine myocardial function or quantify complex valvular lesions with greater depth and detail.
Toshiba America Medical Systems Ultrasound business unit director Dan Skyba said: “The Aplio i900 presents a real breakthrough in expanding the clinical utility of ultrasound, offering cardiologists a new tool for fast, safe and confident diagnoses even in technically difficult patient exams.
“The system combines crystal clear image quality with cutting edge clinical applications to make work flow and help clinicians provide the best possible patient care.”
The Aplio i900 facilitates better processing power and examination during ultrasound procedures by offering thinner beam slices and more return information in each image.
It is suitable for contrast, fetal, pediatric, stress echo and transesophageal echocardiography imaging.
The ultrasound features a new beam-forming technology called iBeam, which optimises efficiency of the beam as well as enhances penetration, spatial resolution and contrast resolution.
The device also includes iSense, touch control screens and enables automatic image adjustments with real-time quick scan.
Toshiba Medical is also planning to unveil its forward projected model-based iterative reconstruction soluTion (FIRST) for cardiac exams at the American College of Cardiology (ACC) 2017 annual meeting in Washington, DC in US.
The technology is claimed to make CT exams safer, minimise noise and increase high-contrast spatial resolution to provide better images.